`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 1of 7 PagelD #: 2726
`
`EXHIBIT 2
`EXHIBIT 2
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 2 of 7 PageID #: 2727
`
`Kayali, Kathryn
`From:
`Sent:
`To:
`Cc:
`Subject:
`Attachments:
`
`Counsel,
`
`Patel, Priyata <Priyata.Patel@weil.com>
`Tuesday, June 18, 2024 10:31 AM
`Robert Oakes; Trask, Andrew; SERVICE - Formycon Team
`Eylea; Eylea Biosimilars; REGENERONPATENT@lists.kellogghansen.com
`RE: Regeneron v. Formycon, 23-cv-97 (NDWVa)
`Boyle Formycon Decl [Highlighted & Excerpted].pdf; Boyle040524Mini_S1 [Highlighted &
`Excerpted].pdf; Boyle040524Mini_S2 [Highlighted & Excerpted].pdf; Forrest040324Mini [Highlighted
`& Excerpted].pdf
`
`It has now been over two months since Regeneron made the below request for redacted copies of Dr. Forrest’s
`deposition transcript and Dr. Boyle’s deposition transcripts and declaration. Formycon has failed to comply. Formycon
`previously contended that it is not required to “parse each line of testimony to determine whether particular questions
`do or do not implicate confidential information.” But Formycon need not “parse” each line of testimony because
`Regeneron has provided Formycon with a short list of lines from each transcript/declaration that it contends does not
`contain confidential information. Additionally, Regeneron has now further limited its request to only the documents
`pertaining to Dr. Boyle and Dr. Forrest (and excluded the transcripts of Dr. Prentice and Dr. Barron). Regeneron’s
`request is therefore narrow and would not be onerous for Formycon. Indeed, Formycon has now provided redactions to
`a number of documents pursuant to the parties’ stipulation regarding redactions, and yet, has failed to respond to
`Regeneron’s request.
`
`By close of business 6/20, confirm whether Formycon agrees with Regeneron regarding the non‐confidential nature of
`the below information and, if not, identify which lines Formycon considers confidential or OCEO and provide an
`explanation supporting its designations.
`
`Boyle Final Tr. 1
`
`22:16‐20; 23:11‐24:4; 25:18‐26:17; 34:12‐20; 38:19‐39:1; 39:9‐41:2;
`45:9‐15; 46:9‐20; 52:16‐53:12; 54:17‐55:11; 57:14‐58:12; 64:3‐6;
`69:12‐70:7; 72:13‐19; 84:17‐85:3; 88:22‐99:2
`191:10‐192:5
`10:18‐14:5; 20:9‐21:18; 104:21‐108:5; 130:5‐145:22; 147:5‐156:11;
`159:1‐164:19; 201:8‐213:10; 222:7‐226:2; 238:5‐263:3
`Boyle Declaration ¶ 81
`
`Boyle Final Tr. 2
`Forrest Final Tr.
`
`Thanks,
`Priya
`
`From: Robert Oakes <RMO@FR.com>
`Sent: Monday, April 15, 2024 9:55 PM
`To: Patel, Priyata <Priyata.Patel@weil.com>; Trask, Andrew <atrask@wc.com>; SERVICE ‐ Formycon Team <SERVICE‐
`Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa)
`
`Priya,
`
`1
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 3 of 7 PageID #: 2728
`
`As we have explained repeatedly in various correspondence, the deposition transcripts of Formycon’s witnesses are
`properly designated as either Confidential or Outside Counsel’s Eyes Only under the Protective Order. As Regeneron is
`well aware, Formycon is not required to parse each line of the confidential transcripts to determine whether particular
`questions do or do not implicate confidential information. There is no provision in the Protective Order that requires a
`party to do so, and Regeneron has not even attempted to argue that there is such a requirement. Please cease your
`repeated attempts to misuse Regeneron’s confidential information. The deposition transcripts of Formycon’s witnesses
`must be treated in accordance with their confidentiality designations unless and until the Court orders otherwise.
`
`
`Regards,
`
`
`Bob
`
`
`Robert M. Oakes :: Principal :: Fish & Richardson P.C.
`222 Delaware Avenue 17th Floor, P.O. Box 1114, Wilmington, DE 19899
`302 778 8477 direct :: oakes@fr.com
`
`
`
`
`From: Patel, Priyata <Priyata.Patel@weil.com>
`Sent: Saturday, April 13, 2024 3:52 PM
`To: Robert Oakes <RMO@FR.com>; Trask, Andrew <atrask@wc.com>; SERVICE ‐ Formycon Team <SERVICE‐
`Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa)
`
`
`Counsel for Formycon,
`
`
`You have yet again failed to comply with Regeneron’s request. Though we are not obligated to do so, we have provided
`below a table of citations to information that Regeneron contends does not contain any OCEO information or Formycon
`confidential information. For ease of reference, we have also attached excerpts of the relevant transcripts containing
`highlighting that reflects those same citations. By close of business Monday, let us know whether Formycon agrees
`with Regeneron regarding the non‐confidential nature of this information and, if not, identify which lines Formycon
`considers confidential or OCEO and provide an explanation supporting its designations. If Formycon fails to do so by
`close of business Monday, then Regeneron will understand that the parties are unable to agree upon the status of the
`information listed below.
`
`
`Boyle Final Tr. 1
`
`22:16‐20; 23:11‐24:4; 25:18‐26:17; 34:12‐20; 38:19‐39:1; 39:9‐41:2;
`45:9‐15; 46:9‐20; 52:16‐53:12; 54:17‐55:11; 57:14‐58:12; 64:3‐6;
`69:12‐70:7; 72:13‐19; 84:17‐85:3; 88:22‐99:2
`191:10‐192:5
`Boyle Final Tr. 2
`Prentice Rough Tr. 9:8‐10:16; 40:4‐41:12
`Barron Rough Tr.
`43:21‐44:12
`Forrest Final Tr.
`10:18‐14:5; 20:9‐21:18; 104:21‐108:5; 130:5‐145:22; 147:5‐156:11;
`159:1‐164:19; 201:8‐213:10; 222:7‐226:2; 238:5‐263:3
`Boyle Declaration ¶ 81 ‐ “Once a protein is degraded, it will not return to its unmodified
`form. See ¶ 77, supra. Applying that principle, if greater than 2% of the
`protein is not in native conformation at 0 month, greater than 2% of
`the protein will not be in native conformation at the 2‐month
`timepoint.”
`
`
`
`2
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 4 of 7 PageID #: 2729
`
`Sincerely,
`Priya
`
`
`From: Robert Oakes <RMO@FR.com>
`Sent: Wednesday, April 10, 2024 10:08 PM
`To: Trask, Andrew <atrask@wc.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa) | Boyle deposition
`
`
`
`
`Andrew,
`
`
`As we stated below, the “Session 1” Boyle deposition transcript is properly designated as Confidential under the
`Protective Order. As non‐limiting examples, in that portion of the transcript you quoted from a confidential portion of
`Dr. Boyle’s report, and asked Dr. Boyle questions reflective of Formycon’s BLA testing. Dr. Boyle’s “Session 2” transcript
`is properly designated as OCEO at least because Regeneron marked Dr. Boyle’s declaration, which is designated OCEO,
`as an exhibit and questioned Dr. Boyle on sections of Formycon’s BLA. Regeneron’s questioning touched on Formycon
`confidential information throughout Dr. Boyle’s deposition, and we are not required to parse each line of testimony to
`determine whether particular questions do or do not implicate confidential information. As Regeneron is well aware, the
`Protective Order contains no such requirement. Regeneron’s continued attempts to misuse Formycon confidential
`information is improper and contrary to the Protective Order.
`
`
`Regards,
`
`
`Bob
`
`
`Robert M. Oakes :: Principal :: Fish & Richardson P.C.
`222 Delaware Avenue 17th Floor, P.O. Box 1114, Wilmington, DE 19899
`302 778 8477 direct :: oakes@fr.com
`
`
`
`
`From: Trask, Andrew <atrask@wc.com>
`Sent: Tuesday, April 09, 2024 1:00 PM
`To: Robert Oakes <RMO@FR.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa) | Boyle deposition
`
`
`Formycon counsel,
`
`
`Regeneron requested that you (1) identify any lines of testimony in pages 1‐125 of the transcript that you believe
`contain Formycon’s confidential information; (2) identify any lines of testimony from page 126‐196 from the transcript
`that you believe are properly designated OCEO; and (3) provide a time today to confer. Your response does none of
`those things. Please comply with these requests immediately so that Regeneron may understand and confer with you
`about your confidentiality designations.
`
`
`The protective order does not restrict the use of nonconfidential information. Your attempt to delay the resolution of
`Regeneron’s challenge to Formycon’s improper confidentiality designations is prejudicial to Regeneron and improperly
`seeks to shield nonconfidential information from the Court.
`
`
`Best,
`
`3
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 5 of 7 PageID #: 2730
`
`Andrew
`
`
`Andrew Trask | Williams & Connolly LLP | 202‐434‐5023 | atrask@wc.com
`
`
`From: Robert Oakes <RMO@FR.com>
`Sent: Monday, April 8, 2024 22:08
`To: Trask, Andrew <atrask@wc.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea <Eylea@wc.com>; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa) | Boyle deposition
`
`
`
`
`Andrew,
`
`
`The “Session 1” transcript from Dr. Boyle’s deposition in the Formycon case contains Formycon confidential information.
`As you are well aware, I designated the deposition transcript confidential at the time you instructed the court reporter
`to break up the transcript, and noted on the record that, as one basis for that designation, your questioning of Dr. Boyle
`on his opinions on the data in Formycon’s BLA, and reading statements from his declaration, which is marked Outside
`Counsel’s Eyes Only. Tr. at 132:8‐133:2. Your statement that “Formycon’s counsel never identified any testimony as
`confidential” is simply untrue. We are not required to pick through all of Dr. Boyle’s testimony, the transcript of which
`we just received this afternoon, and identify each and every instance where confidential information was discussed, and
`we decline to do so. Your attempt to disregard Formycon’s confidentiality designations in order use this information in
`other cases is transparent and improper. The Protective Order expressly provides that “all Protected Material shall be
`used solely for this Action.” D99, ¶7. “Protected Material may not be used under any circumstances for a related,
`separate or foreign action or proceeding…or for any other purpose.” Id. The “Session 1” Boyle transcript is designated
`as “Confidential” under the Protective Order, the “Session 2” Boyle transcript is designated as “Outside Counsel’s Eyes
`Only” under the Protective Order, and those transcripts must be treated in accordance with those designations unless
`and until the Court orders otherwise. D99, ¶21.
`
`
`These confidentiality designations were expressly made on the record at Dr. Boyle’s deposition. Tr. at 132:8‐133:2,
`146:14‐147:11. To the extent there is any dispute about that, Formycon hereby designates the “Session 1” Boyle
`transcript as “Confidential” and the “Session 2” Boyle transcript as “Outside Counsel’s Eyes Only” under Paragraph 16 of
`the Protective Order, which we are able to do within 10 days of receipt of the final transcript, which we received today.
`D99, ¶16. Note that the court reporter sent revised versions of the Boyle transcripts with corrected confidentiality
`designations at approximately 5pm ET today, we expect Regeneron to use those corrected versions going forward.
`
`
`Regards,
`
`
`Bob
`
`
`Robert M. Oakes :: Principal :: Fish & Richardson P.C.
`222 Delaware Avenue 17th Floor, P.O. Box 1114, Wilmington, DE 19899
`302 778 8477 direct :: oakes@fr.com
`
`
`
`
`From: Trask, Andrew <atrask@wc.com>
`Sent: Monday, April 08, 2024 3:02 PM
`To: Robert Oakes <RMO@FR.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea@wc.com; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Formycon, 23‐cv‐97 (NDWVa) | Boyle deposition
`
`
`4
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 6 of 7 PageID #: 2731
`
`[This email originated outside of F&R.]
`
`
`
`Formycon counsel,
`
`
`Now that the court reporting service has circulated final versions of Dr. Boyle’s April 5 deposition transcript, I write to
`update the page range below to reflect the final transcript. The first portion of the transcript, which Regeneron
`understands does not contain any Formycon Confidential information, is pages 1‐125 of the final transcript.
`
`In addition, as we discussed at the deposition, we disagree that the second portion of Dr. Boyle’s deposition transcript
`(final transcript pages 126‐196) is properly designated Outside Counsels Eyes Only. If you contend otherwise, please
`include in your response today an identification of the line(s) from that transcript that you believe are properly
`designated OCEO, and we will plan on covering that as well when we confer tomorrow.
`
`
`We look forward to hearing from you by close of business today.
`
`
`Best,
`Andrew
`
`
`Andrew Trask | Williams & Connolly LLP | 202‐434‐5023 | atrask@wc.com
`
`
`From: Trask, Andrew <atrask@wc.com>
`Sent: Saturday, April 6, 2024 11:51
`To: Robert Oakes <RMO@FR.com>; SERVICE ‐ Formycon Team <SERVICE‐Formycon_Team@fr.com>
`Cc: Eylea <Eylea@wc.com>; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com
`Subject: Regeneron v. Formycon, 23‐cv‐97 (NDWVa) | Boyle deposition
`
`
`Formycon counsel,
`
`
`At yesterday’s deposition of Dr. Boyle in the Regeneron v. Formycon case, Regeneron’s counsel indicated that the
`deposition would start with a portion that would not include any confidential information. Regeneron’s counsel asked
`Formycon’s counsel to note on the record if any particular testimony involved Formycon confidential
`information. Formycon’s counsel never identified any testimony as confidential, and yet at the end of this portion of the
`deposition Formycon’s counsel insisted on marking the transcript as confidential.
`
`
`The first portion of the transcript from yesterday’s deposition of Dr. Boyle (i.e., pages 1‐117 of the rough transcript)
`contains no Formycon confidential information. If you disagree, let us know no later than close of business on Monday
`what lines from pages 1‐117 you contend contain Formycon confidential information and what times on Tuesday you
`are available to confer.
`
`
`Any delay in confirming that the transcript is nonconfidential will be understood as an effort to shield improperly the
`Court and Regeneron’s in‐house counsel from information that is plainly nonconfidential.
`
`
`Best,
`Andrew
`
`
`Andrew Trask | Williams & Connolly LLP | 202‐434‐5023 | atrask@wc.com
`
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is privileged and
`
`5
`
`
`
`Case 1:24-cv-00053-TSK Document 18-2 Filed 06/26/24 Page 7 of 7 PageID #: 2732
`
`confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the
`message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank
`you.
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`
`
`The information contained in this email message is intended only for use of the individual or entity named above. If the
`reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended
`recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly
`prohibited. If you have received this communication in error, please immediately notify us by email, postmaster@weil.com,
`and destroy the original message. Thank you.
`
`
`***************************************************************************************************
`*************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential
`and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the
`intended recipient, please contact the sender by reply email and destroy all copies of the original
`message.
`***************************************************************************************************
`*************************
`
`
`
`The information contained in this email message is intended only for use of the individual or entity named above. If the
`reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended
`recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly
`prohibited. If you have received this communication in error, please immediately notify us by email, postmaster@weil.com,
`and destroy the original message. Thank you.
`
`6
`
`